secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2025-03-26T23:59:59+00:00
Accession:  0000950170-25-045227
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics reports FY2024 net loss $79.3M; cash $227M; VMT-α-NET enrollment reaches 30 patients
--------------------------------------------------------------------------------

- Net loss of $79.3M ($1.23 loss per share) vs $46.5M in FY2023; R&D spend doubled to $41.6M.
- Goodwill impairment of $24.1M due to low market cap; cash and investments $227M, funding expected into late 2026.
- VMT-α-NET Phase 1/2a enrolled 30 patients in Cohort 2 as of Feb 2025; no DLTs, one confirmed response.
- IND cleared for PSV359 (FAP-α targeting); first patient dosing expected mid-2025.
- In Feb 2025, sold 3.38M shares under ATM at ~$3.02 for gross proceeds of $10.2M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000095017025045227/0000950170-25-045227-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000095017025045227/catx-20250326.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-045227

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer